Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 07:06 am EST
Fulcrum Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 24.02 million compared to USD 23.74 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.51 a year ago.
For the nine months, net loss was USD 72.58 million compared to USD 83.74 million a year ago. Basic loss per share from continuing operations was USD 1.19 compared to USD 1.97 a year ago.